Recursion Pharmaceuticals Quarterly Cash Flow Statement
NASDAQ: RXRXHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Pre-market: 4.39 +0.69%
Recursion Pharmaceuticals free cash flow
In the quarter ended Jun 30, 2026, Recursion Pharmaceuticals generated -$105.9 million of operating cash flow and spent $44,000 on capital expenditures. That left free cash flow of -$106.0 million, a free-cash-flow margin of -1381.9% of revenue.
Summary generated from market data by MetaCap's automated system. Methodology
Recursion Pharmaceuticals cash flow statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -131.00M | -117.50M | -108.12M | -162.25M | -171.90M | -202.49M | -178.91M | -95.84M | -97.54M | -91.37M | -93.00M | -93.02M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — | — | — | — |
| Depreciation & Amortization | 18.17M | 19.67M | 19.48M | 21.04M | 23.85M | 19.33M | 12.95M | 7.20M | 8.97M | 7.38M | 7.55M | 7.58M |
| Stock-Based Compensation | 19.50M | 22.21M | 23.76M | 25.24M | 26.16M | 36.06M | 30.78M | 18.25M | 16.52M | 16.13M | 16.09M | 16.79M |
| Change in Working Capital | -21.27M | 14.57M | -3.17M | -8.99M | 6.95M | -1.23M | 560.00K | -1.47M | -13.24M | -13.53M | -14.46M | -8.18M |
| Operating Cash Flow | -105.95M | -81.10M | -46.07M | -117.36M | -76.42M | -131.96M | -115.43M | -59.23M | -82.22M | -102.30M | -74.08M | -72.92M |
| Capital Expenditures | -44.00K | -258.00K | -1.24M | -243.00K | -3.15M | -1.83M | -1.30M | -4.56M | -1.18M | -6.65M | -2.07M | -745.00K |
| Investing Cash Flow | -1.96M | -338.00K | -1.24M | -2.55M | -5.81M | -7.27M | 275.46M | -4.56M | -4.18M | -6.65M | -2.49M | -347.00K |
| Debt Repaid | -2.25M | -2.21M | -2.17M | -2.13M | -2.08M | -2.05M | -2.10M | -2.29M | -26.00K | -26.00K | -694.00K | -24.00K |
| Financing Cash Flow | -1.27M | -3.47M | 132.01M | 251.34M | 97.66M | 40.53M | 10.64M | 16.46M | 263.12M | 13.90M | 80.66M | 53.77M |
| Net Change in Cash | -108.36M | -88.74M | 86.78M | 133.30M | 24.69M | -93.87M | 167.19M | -46.92M | 176.60M | -95.28M | 4.22M | -19.62M |
| Free Cash Flow | -105.99M | -81.36M | -47.32M | -117.60M | -79.57M | -133.79M | -116.73M | -63.79M | -83.40M | -108.95M | -76.14M | -73.67M |
This table shows 12 quarterly periods of Recursion Pharmaceuticals's cash flow statement, from Q2 2026 back to Q3 2023, across 11 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow RXRX's reporting calendar. What is a cash flow statement?